TG Therapeutics' Briumvi meets primary endpoint in Phase 3 trial of single-infusion initiation regimen
TGTX•TG Therapeutics said its Phase 3 ENHANCE trial met its primary endpoint, showing equivalent drug exposure and comparable infusion reactions with a single-infusion BRIUMVI initiation regimen.
1. ENHANCE trial results
TG Therapeutics presented Phase 3 ENHANCE trial results at MSToronto2026. The trial met its primary goal, showing equivalent drug exposure and comparable infusion reactions with a single initial infusion instead of two.
2. Other BRIUMVI data
Phase 1 subcutaneous results supported quarterly dosing, which is under evaluation in a fully enrolled Phase 3 trial. Seven-year results showed sustained disease control and a consistent safety profile in relapsing multiple sclerosis.
3. Upcoming presentation
Initial Phase 1 azer-cel results in primary progressive multiple sclerosis are scheduled to be presented October 23, 2026; the abstract is available.
